Firm cofounder to debate use of synthetic intelligence and machine studying functions for precision drugs in neurology
BOSTON, Jan. 24, 2023 /PRNewswire/ — Beacon Biosignals CEO and co-founder Jacob Donoghue, MD, Ph.D., shall be talking on the Precision Drugs World Convention (PMWC) 2023 being held in Silicon Valley from Jan. 25-27, the corporate introduced at the moment.
The PMWC is the foremost precision drugs convention, bringing collectively greater than 2,500 acknowledged leaders, high international researchers, medical professionals and innovators in an effort to speed up the event and unfold of precision drugs. It offers a discussion board for the trade of details about the most recent advances in expertise, scientific implementation, analysis, and in all elements associated to the regulatory and reimbursement sectors.
Dr. Donoghue shall be a part of a panel session titled “AI/ML Functions for Affected person Outcomes Prediction and Scientific Help” on Friday, Jan. 27, from 1 to 2 p.m. on the Santa Clara Conference Heart in Santa Clara, Calif. This session is a part of Monitor 2 (AI & Knowledge Sciences in Drug Discovery & Scientific Analysis) on Day 3 of the annual convention.
The panel shall be moderated by Alex Sherman, a principal affiliate in Neurology at Harvard Medical College and director of the Heart for Innovation and Bioinformatics on the Neurological Scientific Analysis Institute at Massachusetts Basic Hospital (MGH). Along with Dr. Donoghue, confirmed panelists embody:
- Indu Navar, EverythingALS
- Nuray Yurt, Novartis Oncology
- Marie Abele Bind, MGH/Harvard Medical College
Dr. Donoghue accomplished his medical diploma from the Well being Sciences & Know-how program at Harvard Medical College and his Ph.D. in neuroscience from MIT, the place his analysis centered on computational neurophysiology and the consequences of neuroactive compounds on mind community exercise. He co-founded Beacon Biosignals in 2019.
Dr. Donoghue will talk about Beacon’s progress utilizing machine studying to research epileptiform burden and sleep endpoints derived from electroencephalogram (EEG) recordings. Stratifying sufferers based mostly on these insights offers a extra detailed understanding of a affected person’s situation, and might result in extra focused and efficient therapy plans.
The world’s main computational neurodiagnostics firm, Beacon harnesses machine studying that unlocks the ability of EEG information to advance precision medicines for neurologic and psychiatric issues.
About Beacon Biosignals            Â
Beacon’s machine studying platform for EEG permits and accelerates new remedies that rework the lives of sufferers with neurological, psychiatric or sleep issues. By way of novel machine studying algorithms, giant scientific datasets, and advances in software program engineering, Beacon Biosignals empowers biopharma corporations with unparalleled instruments for efficacy monitoring, affected person stratification, and scientific trial endpoints from mind information. For extra data, go to https://beacon.bio/. For careers, go to https://beacon.bio/careers; for partnership inquiries, go to https://beacon.bio/contact. Observe us on Twitter (@Biosignals) or LinkedIn (https://www.linkedin.com/firm/beacon-biosignals).
MEDIA CONTACT
Megan Moriarty
Amendola Communications for Beacon Biosignals
913.515.7530
[email protected]
SOURCE Beacon Biosignals
